Dealmaking and Industry Outlook: Neurological Disease

Dealmaking and Industry Outlook: Neurological Disease published by Decision Resources, Inc. in November, 2009. This report consists of 37 Pages and the price starts from US $ 4600.

Introduction

Abstract

Introduction

The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. The key to future success in this therapy area is a better understanding of the underlying biomarkers, genes, and disease pathways that lead to disease. Pharma companies have scoured the ranks of available drug targets, technologies, and innovation in neurological diseases and have executed a plethora of acquisitions and deals. In this report, we categorize more than 300 deals in the neurological disease industry for a 32-month period including 2007, 2008, and the fi rst eight months of 2009. We assess the neurology market and its major players as well as analyze the deals that companies are executing and the business strategies they are deploying to gain future success.

Questions Answered in This Report

• Decision Resources Pharmaview analysts forecast that the neurology market will grow to $45.2 billion in 2013. Which pharma companies will be the major players in 2013? What will account for much of the fl ux that will be seen in neurology markets from 2008 to 2013?
• Analyzing deals opens up a window to a company' s business strategies. What do the 340 deals in the neurology industry for 2007, 2008, and the fi rst eight months of 2009 say about pharma companies' strategies in this therapy area? What targets were licensed or optioned? What were the largest deals and who were the most prolifi c dealmakers? What merger and acquisition strategies were in play?
• Complications can arise when multiple parties hold rights to the same product and companies get overzealous in their partnering activities? What almost derailed Elan' s Tysabri collaboration with Biogen Idec? Why are Johnson & Johnson and Pfi zer now partners on an immunotherapy program for AD?
• Too many small biotechs have too few products of unknown quality to entice investors in a tight money market to invest. How big of a concern is bankruptcy or liquidation for small neurology companies? Which companies have chosen to survive by reverse merger or consolidation?
• Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates. Why are disease-specifi c disease foundations so important? What disruptive therapies are in development? What technologies are hot?
• Researchers must gain a better understanding of disease pathways because interrupting these pathways is the basis of targeted therapeutic intervention. What recent gene discoveries and disease pathways have been discovered? What new therapeutic approaches might supersede existing therapies in development?

Scope

• Expert commentary: Mechanism of action, mitochondria, misfolded proteins, disease pathogenesis, new therapeutic approach, Medivation, Dimebon, Huntington Study Group.
• Diseases: Amyotrophic lateral sclerosis (ALS), Alzheimer' s disease (AD), epilepsy, Huntington' s disease (HD), insomnia, migraine, multiple sclerosis (MS), Parkinson' s disease (PD), restless legs syndrome (RLS), stroke.
• Therapy area: Market size, top 25 companies, blockbusters, market share, changing franchises, major products, patent expiry, companies gaining and losing the most sales, new genes, new targets and disease pathways, new therapeutic approaches.
• Dealmaking: Analysis of more than 300 deals, deal volume, mega-deals valued at more than $1 billion, deals valued at more than $400 million, most-prolifi c dealmakers, disease-focused nonprofi t organizations, dealmaking pitfalls, Big Pharma collaboration, change of control licensing provisions, disease deals, technology deals.
• Business strategies: Collaborations, codevelopment, co-commercialization, copromotion, strategic alliances, inlicensing, mergers and acquisitions (M&As), divestment, product acquisitions, patent litigation settlements, marketing agreements, marketed product portfolio acquisitions, brand expansion, international expansion, emerging markets, royalty buyouts, manufacturing agreements, options, mega-mergers, targeted acquisitions, activist investors, liquidation, reverse mergers, consolidation, strengthening franchises.
• Targets: Neuronal nicotinic receptors, orexin receptor, beta-amyloid, neuronal potassium channel openers, autophagy pathway targets, alpha-synuclein, neural glial cell markers, selective adhesion molecules, granulocyte-macrophage colony-stimulating factor, fi broblast growth factor receptor 5, interferon-beta, human alpha-fetoprotein, fi broblast growth factor-2, toll-like receptor 9, myelin basic protein, N-type calcium channels, T-type calcium channels, M1 selective muscarinic agonists, Rasrelated guanosine triphosphate-binding proteins, huntingtin, chloride-gated ion channels, presenilin-1 and -2.
• Technologies: Immunotherapy, therapeutic vaccines, biologics, biosimilars, stem cell therapy, predictive screening, cell models, new formulations, disease-modifying therapies, peptides, gene therapy, RNA interference, recombinant proteins, biomarkers, glutathione-coated liposomes, nanobodies, Fcfusion proteins, monoclonal antibodies, knock out mice, acetylcholinesterase.

Mentioned in This Report

23andMe,Abbott,Abiant,Ablynx,Acorda Therapeutics,Actelion,ActiveSight,Affi ris,Albany Molecular Research,ALS Therapy Development,Institute,Alzheimer' s Drug Discover,Foundation,Ambrx,Apitope International,Aptagen,Arrayit,Ascend Therapeutics,Asklepios Biopharmaceutical,Astellas Pharma,AstraZeneca,Aurigene Discovery Technologies,Banner Alzheimer' s Institute,Barr Pharmaceuticals,Bayer Schering Pharma,Bial,BioArctic Neuroscience,BioFocus,Biogen Idec,BioMS Medical,Bionomics,BioSeek,Boda Pharmaceutical,Boehringer Ingelheim,Breckenridge Pharmaceutical,Buck Institute for Age Research,California Stem Cell,Cambridge Cognition,Cardiff University,Cellumen,Centre Nationale de la Recherche,Scientifi que,Cephalon,Cerebricon,Charles River Laboratories,CHDI Foundation,Chugai,Cobalt Pharmaceuticals,Collaborative Drug Discovery,CoMentis,Dalton Chemical Laboratories,DanioLab,Dr. Reddy' s Laboratories,Duramed,Edunn Biotechnology,Eisai,Elan,Eli Lilly,Evotec,Fast Forward,Forest,Genentech,Genzyme,GlaxoSmithKline,GlobalStem,Globepan Resources,Hamilton Pharmaceuticals,Harvard Medical School,H. Lundbeck,Huntington Study Group,Hypnion,Immuno-Biological Laboratories,Ingenuity Systems,Institut Pasteur de Lille,Intellect Neurosciences,Invitrogen,Ipsen,Janssen Alzheimer,Immunotherapy,Johns Hopkins University,Johnson & Johnson,Jubilant Biosys,Kali Laboratories,LifeHealth,Lundbeck,M' s Science,Meda,Medical Research Council,Medivation,Mental Health Research Institute,of Melbourne,Merck & Co.,Merck KGaA,Merck Serono,Michael J. Fox Foundation,Microbix Biosystems,Millipore,Mitsubishi Tanabe Pharma,MultiCell Technologies,Myelin Repair Foundation,Mylan Laboratories,Neuralstem,Neuren Pharmaceuticals,Neurobiological Technologies,NeuroSearch,Northwestern University,Novacea,NovaMed Pharmaceuticals,NovaQuest,Novartis,Noxxon Pharma,Oligomerix,Omeros,Opexa Therapeutics,Orion,Otsuka,Ovation Pharmaceuticals,P2D Biosciences,Parexel,Parkinson' s Institute,Peptimmune,Pfi zer,Pharmatrophix,Phytopharm,Portola Pharmaceuticals,Prasco Laboratories,Q Therapeutics,RemeGenix,Royalty Pharma,Salk Institute,Samaritan Pharmaceuticals,Sanofi -Aventis,Sepracor,Serenex,SGC Pharma,Shanghai Institute for Biological,Sciences,Simcere Pharmaceutical,Solvay,Stem Cell Sciences,Summit,Takeda,Targacept,Teikoku Pharma,Teva,Texas Institute for Genomic,Medicine,TorreyPines Therapeutics,Transcept Pharmaceuticals,UCB,University of Cambridge,Valeant Pharmaceuticals,Varinel,Vernalis,Vertex,Vitae Pharmaceuticals,Washington University,Watson Pharmaceuticals,Wyeth,XenoPort,ZymoGenetics

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Changing Opportunities
• Spectrum' s Coverage of Central Nervous System Diseases
• Neurology Industry: Market Size and Major Players
  • Top Players
  • Changing Neurology Franchises
  • Impact of Patent Expiry
• Largest Deals and Dealmakers
  • Deal Volume
  • Largest Deals
  • Most Prolifi c Dealmakers
    • GlaxoSmithKline
    • H. Lundbeck
    • Elan
  • Neurology-Focused Foundations
• Big Pharma Collaboration and Pitfalls
• Disease and Technology Deals
  • Deals By Disease Category
  • Deals by Technology
  • Antibody Deals
  • Recombinant Protein Deals
  • Therapeutic Vaccine Deals
• Staying Alive - or Not
  • Liquidation
  • Reverse Merger
  • Consolidation
• Mergers and Acquisitions
• New Genes and Pathways Suggest the Possibility of New Targeted Therapies
  • A Potential New Mechanism of Action Involving Mitochondria
  • New Genes and Pathway Discoveries
• Disruptive Technologies
• Industry Outlook

Expert Commentary

• Potential New Mechanism of Action for the Treatment of Neurodegenerative Diseases
  • David Hung, M.D., President and CEO, Medivation, Inc.

Tables

• 1. Neurological Diseases: Most Prolifi c Corporate Dealmakers, 2007-2009
• 2. Neurological Diseases: Most Prolifi c Nonprofi t Dealmakers, 2007-2009

Figures

• 1. Central Nervous System Diseases: Projected Worldwide Sales, 2008-2015
• 2. Neurological Diseases: Top 25 Companies Based on Worldwide Neurology Sales, 2008 and 2013
• 3. Neurological Diseases: Market Share of Top Companies, 2008 and 2013
• 4. Neurological Diseases: Deal Volume Based on Potential Deal Size, 2007-2009
• 5. Neurological Diseases: The Largest Deals, 2007-2009
• 6. Neurological Diseases: Most Prolifi c Dealmakers, 2007-2009
• 7. Neurological Diseases: Deals By Disease Category, 2007-2009
• 8. Neurological Diseases: Deals by Technology, 2007-2009
• 9. Neurological Diseases: Mergers and Acquisitions, 2007-2009

Related Reports